Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence

Autor: Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF Jr

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 19, Pp 2639-2655 (2023)

Tuan Vu,1 Heinz Wiendl,2 Masahisa Katsuno,3 Stephen W Reddel,4 James F Howard Jr5 1Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA; 2Department of Neurology with Institute of Translational Neurology, U

Externí odkaz: https://doaj.org/article/d1779e825ae241219d0e9fca0cdbccf5

US Clinical Practice Experience with Eculizumab in Myasthenia Gravis: Acute Clinical Events and Healthcare Resource Utilization.

Autor: Nowak RJ; Yale University School of Medicine, New Haven, CT, USA., Habib AA; University of California, Irvine, CA, USA., Klink AJ; Cardinal Health, Dublin, OH, USA., Muppidi S; Stanford Neuroscience Health Center, Palo Alto, CA, USA., Parthan A; Alexion, AstraZeneca Rare Disease, Boston, MA, USA.; FibroGen Inc., San Francisco, CA, USA., Sader SC; Alexion, AstraZeneca Rare Disease, Boston, MA, USA., Balanean A; Cardinal Health, Dublin, OH, USA., Gajra A; Cardinal Health, Dublin, OH, USA.; Hematology-Oncology Associates of CNY, E. Syracuse, NY, USA., Howard JF Jr; Department of Neurology, The University of North Carolina, 170 Manning Drive, CB #7025, Chapel Hill, NC, 27599, USA. howardj@neurology.unc.edu.

Publikováno v: Drugs - real world outcomes [Drugs Real World Outcomes] 2024 Oct 29. Date of Electronic Publication: 2024 Oct 29.

Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis.

Autor: Dewilde S; Services in Health Economics, Brussels, Belgium. Electronic address: sd@she-consulting.be., Griffiths A; Services in Health Economics, Brussels, Belgium., Qi CZ; argenx, Boston, MA, USA., Phillips G; argenx, Boston, MA, USA., Gelinas D; argenx, Boston, MA, USA., Brauer E; argenx, Boston, MA, USA., Mantegazza R; Fondazione IRCCS, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy; Associazione Italiana Miastenia e Malattie Immunodegenerative, Milan, Italy., Howard JF Jr; The University of North Carolina School of Medicine, Department of Neurology, Chapel Hill, NC, USA.

Publikováno v: Journal of the neurological sciences [J Neurol Sci] 2024 Nov 15; Vol. 466, pp. 123264. Date of Electronic Publication: 2024 Oct 04.

Maintenance of zilucoplan efficacy in patients with generalised myasthenia gravis up to 24 weeks: a model-informed analysis.

Autor: de la Borderie G; UCB, 420 rue d'Estienne d'Orves, Colombes 92700, France., Chimits D; UCB, Colombes, France., Boroojerdi B; UCB, Monheim, Germany., Brock M; UCB, Morrisville, NC, USA., Duda PW; UCB, Cambridge, MA, USA., Grimson F; UCB, Slough, UK., Mahoney P; UCB, Slough, UK., Strimenopoulou F; UCB, Slough, UK., Cutter G; Department of Biostatistics, The University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA., Aban I; Department of Biostatistics, The University of Alabama at Birmingham School of Public Health, Birmingham, AL, USA., Brauner S; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.; Department of Neurology, Karolinska University Hospital, Stockholm, Sweden., Petersson M; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden., Howard JF Jr; Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Bennett N; UCB, Morrisville, NC, USA.

Publikováno v: Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2024 Sep 21; Vol. 17, pp. 17562864241279125. Date of Electronic Publication: 2024 Sep 21 (Print Publication: 2024).

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).

Autor: Howard JF Jr; Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: howardj@neurology.unc.edu., Vu T; Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA., Li G; Medsol Clinical Research Center, Port Charlotte, FL, USA., Korobko D; Regional Centre for Multiple Sclerosis and Other Autoimmune System Diseases of the Nervous System, State Novosibirsk Regional Clinical Hospital, Novosibirsk State Medical University, Novosibirsk, Russia., Smilowski M; Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland., Liu L; argenx, Ghent, Belgium., Gistelinck F; argenx, Ghent, Belgium., Steeland S; argenx, Ghent, Belgium., Noukens J; Curare Consulting, Liempde, the Netherlands., Van Hoorick B; argenx, Ghent, Belgium., Podhorna J; argenx, Ghent, Belgium., Borgions F; argenx, Ghent, Belgium., Li Y; Neuromuscular Center, Cleveland Clinic, Cleveland, OH, USA., Utsugisawa K; Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan., Wiendl H; Department of Neurology, University of Münster, Münster, Germany., De Bleecker JL; Department of Neurology and Neuromuscular Reference Center, Ghent University Hospital, Ghent, Belgium., Mantegazza R; Department of Neuroimmunology and Neuromuscular Diseases, Fondazione Istituto Neurologico Carlo Besta, Milan, Italy.

Publikováno v: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2024 Sep; Vol. 21 (5), pp. e00378. Date of Electronic Publication: 2024 Sep 02.